Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Smiths Group beats full-year guidance, but slowdown expected

(Sharecast News) - Engineering business Smiths Group delivered strong annual results on Tuesday, with organic growth coming in ahead of twice-raised guidance and profits up by double digits - though a slight slowdown is expected over the coming year. Group revenues totalled £3.34bn over the 12 months to 31 July, up 6.5% over the year before, with organic group revenues up 8.9%, well ahead of most recent target of 6-8% growth.

All of Smiths Group's businesses contributed positively to organic growth, with double-digit improvements seen in Smiths Interconnect (+22.5%) and Smiths Detection (+15.2%), tempered by more subdued performances at John Crane (+3.0%) and Flex-Tek (+4.4%).

"We exceeded our guidance despite the uncertain macro and tariff environment, a challenging US construction market and interruption from the cyber security incident in January, with the most notable impact being in John Crane," the company said.

Operating profits were 10.3% higher at £580m, rising 13.1% on an organic basis, helped by the operating profit margin rising by 60 basis points to 17.4% - the top end of the 40-60bp guidance range.

Operating cash conversion also improved to 99% from 97%, well ahead of the 90% level expected.

Looking ahead, the company said that separation processes for Smiths Interconnect and Smiths Detection were progressing, with an announcement on Smiths Interconnect expected before the end of 2025.

In terms of financial targets, Smiths Group pointed to a slight slowdown over the current financial year, guiding to organic revenue growth of 4-6%, citing ongoing macro uncertainty "with tariffs and increased geo-political risks causing market instability". This is below the 7.4% average organic revenue growth recorded over the past four years.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.